Market research
4LS.F Athersys, Inc
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 44M
- P/E ratio
- Not available
- Analyst target
- 5.75
- Dividend yield
- 0.0%
- Beta
- -1.26
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 44M
- P/E ratio
- Not available
- Analyst target
- 5.75
- Dividend yield
- 0.0%
- Beta
- -1.26
About
About Athersys, Inc
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Research context
Athersys, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4LS.F discussion.
5 years, 7 months ago
Athersys, Inc is currently in a long term downtrend where the price is trading 18.7% below its 200 day moving average.
From a valuation standpoint, the stock is 81.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 241.2.
Athersys, Inc's total revenue rose by 342.5% to $1M since the same quarter in the previous year.
Its net income has dropped by 123.8% to $-22M since the same quarter in the previous year.
Finally, its free cash flow fell by 71.9% to $-18M since the same quarter in the previous year.
Based on the above factors, Athersys, Inc gets an overall score of 2/5.